Article
Oncology
Guillermo Garcia-Manero, Valeria Santini, Antonio Almeida, Uwe Platzbecker, Anna Jonasova, Lewis R. Silverman, Jose Falantes, Gianluigi Reda, Francesco Buccisano, Pierre Fenaux, Rena Buckstein, Maria Diez Campelo, Stephen Larsen, David Valcarcel, Paresh Vyas, Valentina Giai, Esther Natalie Oliva, Jake Shortt, Dietger Niederwieser, Moshe Mittelman, Luana Fianchi, Ignazia La Torre, Jianhua Zhong, Eric Laille, Daniel Lopes de Menezes, Barry Skikne, C. L. Beach, Aristoteles Giagounidis
Summary: CC-486 significantly improved RBC-TI rate and induced durable bilineage improvements in patients with LR-MDS and high-risk disease features. However, more early deaths occurred in the CC-486 arm, most related to infections in patients with significant pretreatment neutropenia. Further evaluation of CC-486 in MDS is needed.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Oncology
Guillermo Garcia-Manero, Hartmut Doehner, Andrew H. Wei, Ignazia La Torre, Barry Skikne, C. L. Beach, Valeria Santini
Summary: This report reviews the potential use of orally bioavailable azacitidine (Oral-AZA) in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) and its unique pharmacokinetic and pharmacodynamic profile compared to injectable azacitidine. It also discusses the clinical safety and efficacy of Oral-AZA maintenance therapy in AML patients and for the treatment of patients with active MDS, as well as ongoing clinical trials.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
Article
Hematology
Peter Martin, Nancy L. Bartlett, Julio C. Chavez, John L. Reagan, Sonali M. Smith, Ann S. LaCasce, Jeffrey Jones, James Drew, Chengqing Wu, Erin Mulvey, Maria Revuelta, Leandro Cerchietti, John P. Leonard
Summary: This study investigates the use of CC-486 (oral azacitidine) in combination with R-CHOP in previously untreated intermediate- to high-risk DLBCL or grade 3B/transformed follicular lymphoma. The results show that CC-486 can be safely administered before R-CHOP and has a high overall response rate in these patients.
Review
Cell Biology
Chin-King Looi, Lian-Chee Foong, Felicia Fei-Lei Chung, Alan Soo-Beng Khoo, Ee-Mun Loo, Chee-Onn Leong, Chun-Wai Mai
Summary: This review provides updated understanding of the roles of epigenetic factors in regulating EBV latent gene expression and promoting NPC progression. The crosstalk between epigenetic mechanisms and immune evasion in NPC is explored, along with the potential roles of DNMT and HDAC inhibitors in reversing immune suppression and augmenting antitumour immunity. Furthermore, the advantages of combining epigenetic therapy and immune checkpoint inhibitor to reverse immune resistance and improve clinical outcomes are highlighted.
CELL BIOLOGY AND TOXICOLOGY
(2023)
Article
Oncology
Yunliang Lu, Xiaohui Zhou, Weilin Zhao, Zhipeng Liao, Bo Li, Peipei Han, Yanping Yang, Xuemin Zhong, Yingxi Mo, Ping Li, Guangwu Huang, Xue Xiao, Zhe Zhang, Xiaoying Zhou
Summary: ACAT1, as a key enzyme in the ketone body metabolism pathway, plays a crucial role in the proliferation and metastasis of nasopharyngeal carcinoma (NPC), potentially acting as a tumor suppressor by regulating epithelial-mesenchymal transition.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Jiansheng Li, Dongzhi Li, Xianhua Zhang, Cuijuan Li, Fengjuan Zhu
Summary: SLC9A3-AS1 is highly expressed in nasopharyngeal carcinoma (NPC) and affects patient overall survival. Through the modulation of the miR-486-5p/E2F6 axis, it regulates cell proliferation, migration, invasion, and apoptosis. The newly identified SLC9A3-AS1/miR-486-5p/E2F6 pathway may offer attractive therapeutic targets for future development.
Review
Cell Biology
Yingyi Chen, Siyan Liu, Lili Wu, Yitong Liu, Juan Du, Zhenhua Luo, Junji Xu, Lijia Guo, Yi Liu
Summary: Appropriate responses to inflammation are important for pathogen elimination and tissue repair, while uncontrolled inflammation can lead to tissue damage. CCL2, a chemokine and activator of monocytes, macrophages, and neutrophils, plays a key role in amplifying and accelerating the inflammatory cascade and is closely related to chronic non-controllable inflammation. Understanding the regulatory mechanisms of CCL2 can provide potential targets for the treatment of inflammatory diseases.
CELL PROLIFERATION
(2023)
Article
Hematology
Jia Ruan, Alison Moskowitz, Neha Mehta-Shah, Lubomir Sokol, Zhengming Chen, Nikita Kotlov, Grigorii Nos, Maria Sorokina, Vladislav Maksimov, Andrea Sboner, Michael Sigouros, Koen van Besien, Steven Horwitz, Sarah C. Rutherford, Erin Mulvey, Maria V. Revuelta, Jenny Xiang, Alicia Alonso, Ari Melnick, Olivier Elemento, Giorgio Inghirami, John P. Leonard, Leandro Cerchietti, Peter Martin
Summary: This study evaluated oral azacitidine plus CHOP as initial treatment for PTCL, and found that CC-486 treatment resulted in a CR of 75%, with a higher CR rate in PTCL-TFH. CC-486 priming contributed to the reprograming of the tumor microenvironment.
Article
Oncology
Jianxia Wei, Mengna Li, Shipeng Chen, Changning Xue, Lemei Zheng, Yumei Duan, Hongyu Deng, Songqing Fan, Wei Xiong, Ming Zhou
Summary: circBRD7 forms a positive feedback loop with BRD7 to inhibit the tumor growth and metastasis of nasopharyngeal carcinoma (NPC). Low expression of circBRD7 is positively correlated with BRD7 expression and negatively correlated with the clinical stage of NPC patients.
Review
Immunology
Wenting Li, Xiaobing Duan, Xingxing Chen, Meixiao Zhan, Haichuan Peng, Ya Meng, Xiaobin Li, Xian-Yang Li, Guofu Pang, Xiaohui Dou
Summary: Epstein-Barr virus (EBV) is the first tumor virus in humans, and nasopharyngeal carcinoma (NPC) accounts for 60% of new tumor cases caused by EBV worldwide annually. Over 90% of patients with undifferentiated NPC are infected with EBV. Immunotherapy has shown significant breakthroughs in the treatment of recurrent or metastatic NPC, providing a broad prospect for NPC immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, Research & Experimental
Mei Lin, Xiao-Long Zhang, Xiong Zou, Rui You, Qi Yang, Xiong Zou, Kai Yu, You-Ping Liu, Ru-Hai Zou, Yi-Jun Hua, Pei-Yu Huang, Jin Wang, Qi Zhao, Xiao-Bing Jiang, Jun Tang, Yang-Kui Gu, Tao Yu, Gui-Ping He, Yu-Long Xie, Zhi-Qiang Wang, Ting Liu, Si-Yuan Chen, Zhi-Xiang Zuo, Ming-Yuan Chen
Summary: By sequencing samples from 26 nasopharyngeal carcinoma patients, it was found that NPC has a higher neoantigen load compared to other cancers. Neoantigen depletion was more severe in metastatic sites, with the reduction occurring during metastasis.
Review
Oncology
Wai Tong Ng, James C. H. Chow, Jonathan J. Beitler, June Corry, William Mendenhall, Anne W. M. Lee, K. Thomas Robbins, Sandra Nuyts, Nabil F. Saba, Robert Smee, William A. Stokes, Primoz Strojan, Alfio Ferlito
Summary: This article discusses the considerations, practical pearls, and recent advances in radiotherapy for nasopharyngeal carcinoma (NPC), emphasizing the importance of optimal radiotherapy planning and precise beam delivery for treatment efficacy.
Article
Radiology, Nuclear Medicine & Medical Imaging
Xue-Song Sun, Zhi-Wen Xiao, Sai-Lan Liu, Rui Sun, Dong-Hua Luo, Qiu-Yan Chen, Hai-Qiang Mai
Summary: This study developed and validated a nomogram model to predict the overall survival of patients with nasopharyngeal carcinoma without distant metastasis. The model incorporates clinical characteristics, serum biomarkers, and the presence of nasopharyngeal necrosis.
EUROPEAN RADIOLOGY
(2023)
Review
Otorhinolaryngology
Yue Yuan, Fei Ye, Jian-Hui Wu, Xiao-Yan Fu, Zhong-Xi Huang, Tao Zhang
Summary: This paper reviews recent advances in early screening for nasopharyngeal carcinoma (NPC) and cell-free DNA (cfDNA) methylation, highlighting the low positive predictive value (PPV) of current screening methods and the potential of combining cfDNA methylation analysis with Epstein-Barr virus (EBV) serological testing to improve PPV.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2023)
Review
Medical Laboratory Technology
Yiwen Liu, Jianping Wen, Weiguo Huang
Summary: Exosomes play important roles in nasopharyngeal carcinoma by manipulating the tumor microenvironment, participating in chemotherapy and radiation resistance, inducing immune suppression, promoting pathological angiogenesis, and supporting metastasis. They have the potential to be diagnostic biomarkers but face technical challenges in large-scale applications.
CLINICA CHIMICA ACTA
(2021)
Article
Biophysics
Marco Bologna, Giuseppina Calareso, Carlo Resteghini, Silvana Sdao, Eros Montin, Valentina Corino, Luca Mainardi, Lisa Licitra, Paolo Bossi
Summary: In this study, radiomics-based predictive models were built for sinonasal cancers to predict response to induction chemotherapy. Different types of MRI images were used to extract radiomic features, and the relevance of ADC-based radiomics in predicting response to chemotherapy was highlighted.
NMR IN BIOMEDICINE
(2022)
Correction
Oncology
Alice Baggi, Pietro Quaglino, Marco Rubatto, Roberta Depenni, Michele Guida, Paolo Antonio Ascierto, Claudia Trojaniello, Paola Queirolo, Maristella Saponara, Ketty Peris, Francesco Spagnolo, Luca Bianchi, Federica De Galitiis, Maria Concetta Potenza, Ilaria Proietti, Riccardo Marconcini, Andrea Botticelli, Vito Barbieri, Lisa Licitra, Salvatore Alfieri, Corrado Ficorella, Alessio Cortellini, Maria Concetta Fargnoli, Teresa Troiani, Luca Tondulli, Manuel Zamparini, Paolo Bossi
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Amelia Barcellini, Giulia Fontana, Daria Maria Filippini, Sara Ronchi, Maria Bonora, Barbara Vischioni, Rossana Ingargiola, Anna Maria Camarda, Pierre Loap, Nadia Facchinetti, Lisa Licitra, Guido Baroni, Ester Orlandi
Summary: This study assesses the prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and blood chemistry in head and neck adenoid cystic carcinoma (ACC) patients treated with carbon ion radiotherapy (CIRT). The results suggest that pre-treatment NLR and hemoglobin values may serve as independent prognostic factors for clinical outcomes in ACC patients.
RADIOTHERAPY AND ONCOLOGY
(2022)
Review
Oncology
Stefano Cavalieri, Imperia Nuzzolese, Lisa Licitra
Summary: Patients with HPV positive oropharyngeal carcinoma require deintensified treatment options to reduce treatment toxicity without compromising outcomes, but there is currently insufficient high-level data to support these interventions. Clinical trials are needed to define risk-based deescalation strategies for this patient population.
SEMINARS IN ONCOLOGY
(2022)
Article
Cell Biology
Stefano Cavalieri, Mara Serena Serafini, Andrea Carenzo, Silvana Canevari, Deborah Lenoci, Federico Pistore, Rosalba Miceli, Stefania Vecchio, Daris Ferrari, Cecilia Moro, Andrea Sponghini, Alessia Caldara, Maria Cossu Rocca, Simona Secondino, Gabriella Moretti, Nerina Denaro, Francesco Caponigro, Emanuela Vaccher, Gaetana Rinaldi, Francesco Ferrau, Paolo Bossi, Lisa Licitra, Loris De Cecco
Summary: This study evaluates the prognostic significance of a four-gene inflammatory signature in recurrent/metastatic head and neck squamous cell carcinoma patients treated with the EGFR inhibitor cetuximab plus chemotherapy. The results show that patients with high values of the signature have significantly better progression-free survival and overall survival compared to those with intermediate and low values. The signature also correlates with treatment response.
Review
Oncology
Elena Colombo, Arianna Ottini, Lisa Licitra
Summary: The purpose of this review is to address the treatment options for patients with slowly progressive and/or symptomatic oligometastatic radioactive iodine refractory (RAIR) differentiated thyroid carcinomas (DTCs). The recent literature on this topic has not been extensively reviewed in previous publications, and this review aims to fill the gaps in knowledge.
CURRENT OPINION IN ONCOLOGY
(2023)
Article
Oncology
Stefano Cavalieri, Paolo Bossi, Gabriele Infante, Rosalba Miceli, Nicola Alessandro Iacovelli, Eliana Ivaldi, Laura Deborah Locati, Cristiana Bergamini, Carlo Resteghini, Imperia Nuzzolese, Salvatore Alfieri, Elena Colombo, Rossana Ingargiola, Marzia Franceschini, Giuseppina Calareso, Lisa Licitra, Ester Orlandi
Summary: The study analyzed 324 patients with loco-regionally advanced head and neck cancers, finding that older patients had more comorbidities and received less intensive treatments. However, after adjusting for various factors, there were no significant differences in terms of survival according to age.
Review
Oncology
Elena Colombo, Charlotte Van Lierde, Alexandra Zlate, Alexandra Jensen, Gemma Gatta, Fabio Didone, Lisa F. Licitra, Vincent Gregoire, Vander Vander Poorten, Laura D. Locati
Summary: This article discusses the most common histological diagnoses of salivary gland carcinomas in the elderly population and the corresponding survival outcomes. It also reviews the current therapeutic strategies for locoregionally advanced and metastatic disease, considering the recent advances in precision oncology. The collaboration between the Multidisciplinary Tumor Board and the Geriatrician aims to determine the most appropriate treatment pathway for each elderly patient, focusing on overall functionality rather than chronological age.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Stefano Cavalieri, Imperia Nuzzolese, Arianna Ottini, Cristiana Bergamini, Carlo Resteghini, Elena Colombo, Salvatore Alfieri, Pasquale Quattrone, Giuseppina Calareso, Nicola Alessandro Iacovelli, Marzia Franceschini, Lisa Licitra
Summary: This study aimed to describe the natural history of AR-positive recurrent/metastatic (R/M) salivary gland carcinoma (SGC) patients based on HER2 amplification status. The results showed that HER2 amplification was associated with a higher risk of disease recurrence and death from R/M disease compared to HER2-negative patients, as well as a non-statistically significant higher prevalence of CNS metastases.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Stefano Cavalieri, Claudia Vener, Marissa LeBlanc, Laura Lopez-Perez, Giuseppe Fico, Carlo Resteghini, Dario Monzani, Giulia Marton, Gabriella Pravettoni, Mauricio Moreira-Soares, Despina Elizabeth Filippidou, Aitor Almeida, Aritz Bilbao, Hisham Mehanna, Susanne Singer, Steve Thomas, Luca Lacerenza, Alfonso Manfuso, Chiara Copelli, Franco Mercalli, Arnoldo Frigessi, Elena Martinelli, Lisa Licitra
Summary: Survivors of head and neck cancer face significant burdens and the primary goal is to achieve cancer-free survival with an optimal quality of life (QoL). A clinical trial aims to reduce the proportion of survivors experiencing a clinically relevant reduction in QoL during follow-up using mobile devices. The study will assess the impact of the intervention on global QoL deterioration over a 24-month period.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Maria Vieito, Victor Moreno, Anna Spreafico, Irene Brana, Judy S. Wang, Meir Preis, Tatiana Hernandez, Sofia Genta, Aaron R. Hansen, Bernard Doger, Vladimir Galvao, Laurie Lenox, Regina J. Brown, Anna Kalota, Jaydeep Mehta, Friederike Pastore, Bharvin Patel, Pankaj Mistry, Junchen Gu, Josh Lauring, Manish R. Patel
Summary: In this study, a selective and potent PRMT5 inhibitor was evaluated for its safety and efficacy in advanced malignant solid tumors or non-Hodgkin lymphoma patients. The results showed that the inhibitor demonstrated good anti-tumor activity and manageable toxicity in treating adenoid cystic carcinoma and other tumor types. Two recommended doses were determined based on the study findings. The clinical benefits of the inhibitor in other tumor types were limited.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Neil E. Fleshner, Rashid K. Sayyid, Aaron R. Hansen, Joseph L. K. Chin, Ricardo Fernandes, Eric Winquist, Theodorus van der Kwast, Joan Sweet, Katherine Lajkosz, Miran Kenk, Karen Hersey, Rosette Veloso, Doron Berlin, Jaime O. Herrera-Caceres, Srikala Sridhar, Madeleine Moussa, Antonio Finelli, Robert J. Hamilton, Girish S. Kulkarni, Alexandre R. Zlotta, Anthony M. Joshua
Summary: The addition of neoadjuvant cabazitaxel to abiraterone acetate/leuprolide acetate prior to radical prostatectomy did not improve pathologic complete response or minimal residual disease in localized, high-risk prostate cancer.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Stefano Cavalieri, Viviana Vitolo, Amelia Barcellini, Sara Ronchi, Angelica Facoetti, Chiara Campo, Catherine Klersy, Silvia Molinelli, Francesco Agustoni, Virginia Valeria Ferretti, Annalisa De Silvestri, Marco Platania, Michele Del Vecchio, Marco Durante, Alexander Helm, Claudia Fournier, Filippo de Braud, Paolo Pedrazzoli, Ester Orlandi, Lisa Licitra
Summary: ICONIC is a phase II clinical trial that aims to assess the feasibility and clinical activity of combining carbon ion radiotherapy with immune checkpoint inhibitors in cancer patients. This study will provide controlled data regarding the safety of this novel therapeutic combination, as no previous clinical trials have evaluated it.
Meeting Abstract
Oncology
Marie Morfouace, Aleksandra Stevovic, Julio Oliveira, Nicolas Penel, Julien Peron, Paolo G. Casali, Michael J. Seckl, Jourik A. Gietema, Wouter de Herder, Lucjan Wyrwicz, Christelle de la Fouchardiere, Lisa Licitra, Nicolas Girard, Sophie Piperno-Neumann, Ellen Kapiteijn, Ahmed Idbaih, Jean-Yves Blay
Meeting Abstract
Oncology
Lisa F. Licitra, Mara Serena Serafini, Federico Pistore, Deborah Lenoci, Mario Airoldi, Maria Cossu Rocca, Primoz Strojan, Cvetka Grasic Kuhar, Marco C. Merlano, Nerina Denaro, Francesco Perri, Athanassios Argiris, Cristina Gurizzan, Federica Perrone, Maria Grazia Ghi, Alessandra Cassano, Giacomo Allegrini, Loris De Cecco, Paolo Bossi
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)